Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 10/20 | 0.58 |
| ▸ | MAP3K12 | Q12852 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | KDM5A | P29375 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17886743 | 0.87 | PLA2G1B (0.62) | MAP3K12KMT2ANAMPTALDH1A1LMNA | |
| SCHEMBL17888366 | 0.86 | KDM4E (0.61) | KMT2AKDM4ENAMPT | |
| SCHEMBL6347014 | 0.80 | HSD11B1 (0.53) | PROKR1MAP3K12NAMPTKDM5A | |
| SCHEMBL13212080 | 0.79 | PRMT5 (0.53) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL17888407 | 0.79 | KDM4E (0.52) | KMT2AKDM4E | |
| SCHEMBL4003240 | 0.76 | GPR119 (0.55) | KDM5A | |
| SCHEMBL30919809 | 0.76 | GPR119 (0.55) | KDM5A | |
| SCHEMBL16565554 | 0.75 | ACHE (0.56) | KMT2ANAMPTLMNAHPGD | |
| SCHEMBL167219 | 0.75 | NAMPT (0.58) | MAP3K12KDM4ENAMPTKDM5A | |
| SCHEMBL3456176 | 0.74 | RECQL (0.73) | PROKR1KMT2ANAMPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3041841-B1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2019-06-05 | — | — | EP | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | PROKR1 966/4885MAP3K12 33/4885KMT2A 1797/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | PROKR1 966/4885MAP3K12 33/4885KMT2A 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.